Tempus TIME Network & Next Trials

Tempus TIME Network and Next Trials is a clinical trial enrollment solution designed for life sciences companies and biopharma sponsors seeking to accelerate patient identification, site activation, and enrollment across oncology trials. By combining one of the largest oncology provider networks in the United States with AI-powered patient matching technology, Tempus enables sponsors to bring trials to patients faster — including those in community settings where the majority of cancer care is delivered.

The platform has demonstrated measurable impact across a range of trial types and sponsors. TriHealth achieved a 64% annual increase in patients enrolled in clinical trials, with Tempus TIME driving 95% of that growth. Aadi Bioscience used the TIME program to identify patients with rare TSC1 or TSC2 mutations for its PRECISION 1 trial, while Sermonix shortened its ELAINE-2 trial enrollment by 10 months, achieving first patient in 115 days faster than at traditional sites.

TIME Network Scale and Reach

• Approximately 100 sites representing more than 1,000 clinical locations across the United States
• More than 5 million cancer patients covered within the trial network
• Over 1,500 clinical trials have been active on the network
• Approximately 90% of sites are community-based practices, reflecting where most cancer patients receive care
• Just-in-Time trial activation achievable in approximately 10 business days

Site Activation Models

• Expedited activation: Through streamlined activities and standardized study start-up documentation, sites can be activated in approximately 30 business days prior to identifying the first eligible patient for a trial
• Just-in-Time activation: Utilizing the same operational efficiencies, Tempus can activate new sites in approximately 10 business days once an eligible patient has been identified, enabling rapid deployment at any community location
• The TIME network complements traditional trial sites by bringing studies to patients in the locations where they already receive care, supported by site engagement initiatives and standardized documentation

Tempus Next Trials: AI-Enabled Clinical Trial Technology

• An AI-driven platform designed to support clinical researchers across the full clinical trials spectrum, with a focus on trial portfolio management, prescreening, and performance metrics
• Automates patient pre-screening through multimodal data analysis, helping to identify eligible patients more efficiently
• Optimizes enrollment workflows for clinicians, reducing administrative burden and improving throughput
• Provides self-service tools for cohort building and feasibility research, enabling sponsors to assess trial viability before activation
• An AI-powered screening tool has been shown to screen out approximately 72% of ineligible patients from the initial pool, improving matching efficiency
• Centralizes patient data and rapidly matches patients to suitable trials, as demonstrated in an oral presentation at ASCO

Community Access and Diversity

• 85% of patients with cancer are treated in community centers, and the TIME Network includes hundreds of community site locations across the U.S. to reflect this reality
• The representative patient population across TIME sites supports sponsors' diversity enrollment plans
• The network spans both academic medical centers and community-based practices, enabling trial access for all patients regardless of geographic location
• Just-in-Time activation supports rapid trial deployment at any community location within days

Demonstrated Outcomes and Published Evidence

• Collaboration with Exigent Research Network across independent community oncology practices demonstrated measurable impact on screening, matching, and enrollment over a two-year period
• TriHealth Cancer Institute's EMR integration with Tempus AI TIME enables patient screening using an AI-powered software application (TApp) matched to a broad clinical trial portfolio
• The TIME Precision Network, a dedicated group of investigators across the provider site network, has expanded support for Phase I clinical trials to accelerate activation and enrollment
• Tempus has announced a partnership with OneOncology, a national platform for independent oncology practices, to further broaden patient access to clinical trials

Tempus TIME Network and Next Trials is trusted by hundreds of biopharma companies to support drug development. The solution integrates with existing EHR systems and is designed for US-based trial enrollment, with capabilities spanning research, clinical development, and commercialization. The platform is intended for life sciences companies focused on research and development applications.